This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Integra LifeSciences Now Offers Zero-Profile, Stand-Alone Interbody Devices For Neck And Lumbar Fixation Procedures

PLAINSBORO, N.J., Oct. 24, 2012 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq:IART) today announced the full U.S. market release of the Integra ® Complete Cervical Intervertebral Body Fusion Device (IBD), expanding Integra's spine product portfolio with the addition of a zero-profile, stand-alone IBD for anterior cervical decompression and fusion (ACDF) procedures. The Integra ® Complete Cervical IBD has received 510(k) clearance from the United States Food & Drug Administration (FDA), and is designed to help provide stability for spinal fusion after a diseased cervical disc is surgically removed.

"The stand-alone IBD option is a growing market segment, and Integra is now well positioned within this market with solutions for both the cervical and lumbar regions of the spine," said Kirt Stephenson, President, U.S. Spine.

Traditionally, surgeons use a supplemental fixation plate to help hold an IBD in place. However, the Integra ® Complete Cervical IBD features the benefit of a zero-profile, stand-alone design by utilizing two screws to help secure the IBD in its functional position, eliminating the need for a supplemental fixation plate. The Integra ® Complete Cervical IBD System is a natural complement to the Zuma-C™ stand-alone integrated plate and cervical spacer system. Its design is based on the Vu aPOD™ Prime platform, utilizing one cephalad and one caudal screw to anchor the implant to the vertebral bodies, and offers a wide variety of implant sizes, combined with a comprehensive set of instrumentation.

Integra, a leading provider of fusion implants and orthobiologics used in spinal surgery, now offers stand-alone IBDs for both cervical and lumbar procedures. Stand-alone cervical solutions include the Complete Cervical IBD and the Zuma-C Anterior Cervical Fixation System, and lumbar stand-alone solutions include the Vu aPOD TM Prime and the Zuma  Stand-alone Anterior Lumbar Fixation System. Integra's IBD portfolio also includes the Hollywood™ IBD, Pacifica™ IBD, Vu cPOD™ IBD, Vu ePOD™ IBD, Vu LPOD™ IBD Redondo™ IBD, and Ventura™ IBD.

Integra LifeSciences, a world leader in medical devices, is dedicated to limiting uncertainty for surgeons, so they can concentrate on providing the best patient care. Integra offers innovative solutions in orthopedics, neurosurgery, spine, reconstructive, and general surgery. For more information, please visit www.integralife.com .

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements concerning the products and services provided by Integra. Such forward looking statements involve risks and uncertainties that could cause actual results to differ materially from predicted or expected results. Among other things, the willingness of surgical professionals to use Integra products may affect the prospects for their use in surgical procedures. In addition, the economic, competitive, governmental, technological and other factors, identified under the heading "Risk Factors" included in Item IA of Integra's Annual Report on Form 10-K for the year ended December 31, 2011 and information contained in subsequent filings with the Securities and Exchange Commission could affect actual results.

CONTACT: Gianna Sabella
         Director, Corporate Communications
         (609) 936-2389
         gianna.sabella@integralife.com

Company Logo

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,118.23 +66.50 0.39%
S&P 500 1,985.27 +11.64 0.59%
NASDAQ 4,461.3980 +36.6940 0.83%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto
Advertising Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs